Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-CTR-FAPI in Thyroid Cancer
NCT07438847Phase 1Recruiting
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 177Lu-CTR-FAPI in thyroid cancer. Primary endpoints: Adverse Events at 6 weeks, Dose-Limiting Toxicities at 6 weeks and 1 more. Started Jan 2026; status: recruiting.
02
Drugs
177Lu-CTR-FAPI
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT07438847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07438847.